TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study to Identify the Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Stage III Melanoma Patients
Brief Summary: This is a two-arm Phase 1b feasibility trial consisting of 20 patients receiving the combination of ipilimumab+nivolumab, either adjuvant, or split neo-adjuvant and adjuvant.


Options:
A: Arm Label: Arm A (ipilimumab and sargramostim); Type: EXPERIMENTAL; Interventions: Biological: Ipilimumab, Biological: Sargramostim | Arm Label: Arm B (ipilimumab); Type: ACTIVE_COMPARATOR; Interventions: Biological: Ipilimumab | Intervention Type: BIOLOGICAL; Name: Ipilimumab; Assigned to Arm(s): Arm A (ipilimumab and sargramostim), Arm B (ipilimumab) | Intervention Type: BIOLOGICAL; Name: Sargramostim; Assigned to Arm(s): Arm A (ipilimumab and sargramostim)
B: Arm Label: Arm A; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Arm Label: Arm B; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Surgery of the tumor, Drug: Infusion with ipilimumab 3 mg/kg q3wks, Drug: Infusion with nivolumab 1 mg/kg q3wks | Intervention Type: PROCEDURE; Name: Surgery of the tumor; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with ipilimumab 3 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B | Intervention Type: DRUG; Name: Infusion with nivolumab 1 mg/kg q3wks; Assigned to Arm(s): Arm A, Arm B
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody, Biological: MDX-1379 (gp100) Melanoma Peptide Vaccine | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody | Intervention Type: DRUG; Name: MDX-010 (anti-CTLA4) monoclonal antibody; Assigned to Arm(s): 2, 3 | Intervention Type: BIOLOGICAL; Name: MDX-1379 (gp100) Melanoma Peptide Vaccine; Assigned to Arm(s): 1, 2
D: Intervention Type: BIOLOGICAL; Name: GM2-KLH vaccine; Assigned to Arm(s): N/A | Intervention Type: BIOLOGICAL; Name: QS21; Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: adjuvant therapy; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Nifedipine Alone or Nifedipine Plus Indomethacin for Treatment of Acute Preterm Labor: An Open Label, Randomized Comparative Effectiveness Controlled Trial
Brief Summary: Tocolytic agents are used for the treatment of preterm labor. It is unclear whether combination treatments of two tocolytic agents are more effective in stopping preterm labor compared to one. Therefore, the investigators propose a comparative effective trial of nifedipine plus indomethacin vs. nifedipine alone for the treatment of preterm labor


Options:
A: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: indomethacin; Type: EXPERIMENTAL; Interventions: Drug: indomethacin | Intervention Type: DRUG; Name: indomethacin; Assigned to Arm(s): indomethacin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo
B: Arm Label: Indomethacin group; Type: EXPERIMENTAL; Interventions: Drug: Indomethacin | Arm Label: Nifedipine group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Indomethacin group | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine group
C: Arm Label: Nifedipine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine | Arm Label: Nifedipine plus Indomethacin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nifedipine, Drug: Indomethacin | Intervention Type: DRUG; Name: Nifedipine; Assigned to Arm(s): Nifedipine, Nifedipine plus Indomethacin | Intervention Type: DRUG; Name: Indomethacin; Assigned to Arm(s): Nifedipine plus Indomethacin
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Nifedlipine | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Magnesium | Intervention Type: DRUG; Name: Magnesium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Nifedlipine; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL PIVOTAL - SPYRAL HTN-OFF MED)
Brief Summary: The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the absence of antihypertensive medications.


Options:
A: Arm Label: group Co; Type: ACTIVE_COMPARATOR; Interventions: Device: The HOTMAN® System | Arm Label: group RDN; Type: ACTIVE_COMPARATOR; Interventions: Procedure: The SymplicityTM Renal Denervation System | Intervention Type: PROCEDURE; Name: The SymplicityTM Renal Denervation System; Assigned to Arm(s): group RDN | Intervention Type: DEVICE; Name: The HOTMAN® System; Assigned to Arm(s): group Co
B: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
C: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Device: MDT-2211 Renal Denervation System | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MDT-2211 Renal Denervation System; Assigned to Arm(s): Renal denervation
D: Arm Label: PV isolation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: PV isolation+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: PV isolation+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): PV isolation | Intervention Type: PROCEDURE; Name: PV isolation+renal denervation; Assigned to Arm(s): PV isolation+renal denervation

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension in the Absence of Antihypertensive Medications (SPYRAL PIVOTAL - SPYRAL HTN-OFF MED)
Brief Summary: The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the absence of antihypertensive medications.


Options:
A: Arm Label: Aliskiren; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aliskiren | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Aliskiren; Assigned to Arm(s): Aliskiren | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Renal denervation; Type: EXPERIMENTAL; Interventions: Device: MDT-2211 Renal Denervation System | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: MDT-2211 Renal Denervation System; Assigned to Arm(s): Renal denervation
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
D: Arm Label: Renal artery ablation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Renal artery ablation | Arm Label: Sham; Type: SHAM_COMPARATOR; Interventions: Procedure: Renal angiography | Intervention Type: PROCEDURE; Name: Renal artery ablation; Assigned to Arm(s): Renal artery ablation | Intervention Type: PROCEDURE; Name: Renal angiography; Assigned to Arm(s): Sham

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTN-ON MED)
Brief Summary: The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.


Options:
A: Intervention Type: DEVICE; Name: Symplicty(TM) Catheter System; Assigned to Arm(s): N/A
B: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Procedure: Renal sympathetic denervation | Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: PROCEDURE; Name: Renal sympathetic denervation; Assigned to Arm(s): Renal sympathetic denervation
C: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
D: Arm Label: Renal sympathetic denervation; Type: EXPERIMENTAL; Interventions: Device: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA) | Arm Label: Sham procedure; Type: SHAM_COMPARATOR; Interventions: Other: Sham procedure | Intervention Type: DEVICE; Name: Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA); Assigned to Arm(s): Renal sympathetic denervation | Intervention Type: OTHER; Name: Sham procedure; Assigned to Arm(s): Sham procedure

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Global Clinical Study of Renal Denervation With the Symplicity Spyral™ Multi-electrode Renal Denervation System in Patients With Uncontrolled Hypertension on Standard Medical Therapy (SPYRAL HTN-ON MED)
Brief Summary: The purpose of this study is to test the hypothesis that renal denervation decreases blood pressure and is safe when studied in the presence of up to three standard antihypertensive medications.


Options:
A: Arm Label: Renal Denervation; Type: EXPERIMENTAL; Interventions: Device: Symplicity Spyral™ multi-electrode renal denervation system | Arm Label: Sham Procedure; Type: SHAM_COMPARATOR; Interventions: Procedure: Sham Procedure | Intervention Type: DEVICE; Name: Symplicity Spyral™ multi-electrode renal denervation system; Assigned to Arm(s): Renal Denervation | Intervention Type: PROCEDURE; Name: Sham Procedure; Assigned to Arm(s): Sham Procedure
B: Arm Label: Renal Denervation plus Medications; Type: EXPERIMENTAL; Interventions: Device: Radiofrequency ablation catheter, Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Arm Label: Medications; Type: ACTIVE_COMPARATOR; Interventions: Drug: Amlodipine, losartan potassium and hydrochlorothiazide | Intervention Type: DEVICE; Name: Radiofrequency ablation catheter; Assigned to Arm(s): Renal Denervation plus Medications | Intervention Type: DRUG; Name: Amlodipine, losartan potassium and hydrochlorothiazide; Assigned to Arm(s): Medications, Renal Denervation plus Medications
C: Arm Label: Control group; Type: OTHER; Interventions: Procedure: Renal denervation | Arm Label: Intervention group; Type: EXPERIMENTAL; Interventions: Procedure: Renal denervation | Intervention Type: PROCEDURE; Name: Renal denervation; Assigned to Arm(s): Control group, Intervention group
D: Arm Label: Circumferential PVI; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PV isolation | Arm Label: Circumferential PVI+renal denervation; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Circumferential PVI+renal denervation | Intervention Type: PROCEDURE; Name: Circumferential PV isolation; Assigned to Arm(s): Circumferential PVI | Intervention Type: PROCEDURE; Name: Circumferential PVI+renal denervation; Assigned to Arm(s): Circumferential PVI+renal denervation

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Different Doses of IVIG for Kawasaki Disease: a Multicentre, Prospective, Randomised Trial
Brief Summary: The objective of this study is to investigate the effect of different doses of intravenous immunoglobulin (IVIG) (1g/kg once, 1g/kg twice, 2g/kg once) for Kawasaki disease (KD) in a multicentre, prospective,randomised trial.


Options:
A: Arm Label: IVIG(1g/kg,once); Type: EXPERIMENTAL; Interventions: Drug: IVIG (1g/kg,once) | Arm Label: IVIG(1g/kg,twice); Type: EXPERIMENTAL; Interventions: Drug: IVIG (1g/kg,twice) | Arm Label: IVIG(2g/kg.once); Type: ACTIVE_COMPARATOR; Interventions: Drug: IVIG (2g/kg.once) | Intervention Type: DRUG; Name: IVIG (1g/kg,once); Assigned to Arm(s): IVIG(1g/kg,once) | Intervention Type: DRUG; Name: IVIG (1g/kg,twice); Assigned to Arm(s): IVIG(1g/kg,twice) | Intervention Type: DRUG; Name: IVIG (2g/kg.once); Assigned to Arm(s): IVIG(2g/kg.once)
B: Arm Label: TA-650; Type: EXPERIMENTAL; Interventions: Drug: TA-650 | Arm Label: VGIH; Type: ACTIVE_COMPARATOR; Interventions: Drug: Polyethylene Glycol-treated Human Immunoglobulin (VGIH) | Intervention Type: DRUG; Name: TA-650; Assigned to Arm(s): TA-650 | Intervention Type: DRUG; Name: Polyethylene Glycol-treated Human Immunoglobulin (VGIH); Assigned to Arm(s): VGIH
C: Arm Label: IVIG; Type: ACTIVE_COMPARATOR; Interventions: Drug: IVIG | Arm Label: Infliximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Infliximab | Intervention Type: DRUG; Name: IVIG; Assigned to Arm(s): IVIG | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): Infliximab
D: Arm Label: the standard group; Type: ACTIVE_COMPARATOR; Interventions: Drug: IVIG, Drug: Aspirin | Arm Label: the standard+prednisolone group; Type: EXPERIMENTAL; Interventions: Drug: IVIG, Drug: Aspirin, Drug: Prednisolone | Intervention Type: DRUG; Name: IVIG; Assigned to Arm(s): the standard group, the standard+prednisolone group | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): the standard group, the standard+prednisolone group | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): the standard+prednisolone group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Latino Mothers as Primary Agents of Change
Brief Summary: Entre Familia was a 4-year randomized controlled trial funded by the American Cancer Society. The study was conducted in Imperial County, California, and involved a partnership between the Institute for Behavioral and Community Health at San Diego State University and Clínicas de Salud del Pueblo, Inc. a private, non-profit corporation providing comprehensive primary care services to residents throughout Imperial and Riverside Counties. The investigators enrolled 361 Latina mothers and one of their children aged between 7 and 13 years old; in 25% of families, the father was also enrolled. Participants were randomly assigned to either an intervention or delayed-treatment control condition. The intervention consisted of a community health worker (or promotora)-delivered home-based intervention to promote healthy eating. The promotoras used a telenovela DVD series and accompanying manual, both written and produced by study staff. The intervention was delivered through 11 home visits and 4 support telephone calls over a 4 month period. Participants in the delayed-treatment condition received intervention materials when evaluation assessments had been completed. Evaluation measures were taken at baseline, 4 months (immediate post-intervention) and 10 months (6-months post intervention). Participants completed a self-report interview with study staff at each time point. Height and weight measurements were also collected for the mothers and children. The primary outcomes were changes in mothers' daily fruit and vegetable intake. Secondary outcomes for mothers, children and fathers included changes in fat intake, sugary beverage intake, parenting strategies, and perceived barriers to healthy eating.


Options:
A: Arm Label: Healthy eating blog (HEB); Type: EXPERIMENTAL; Interventions: Behavioral: Healthy eating blog | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Healthy eating blog; Assigned to Arm(s): Healthy eating blog (HEB)
B: Arm Label: motivational counseling; Type: EXPERIMENTAL; Interventions: Behavioral: motivational counseling | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: motivational counseling; Assigned to Arm(s): motivational counseling
C: Arm Label: Home-based promotora intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Home-based promotora family intervention | Arm Label: Delayed treatment control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Home-based promotora family intervention; Assigned to Arm(s): Home-based promotora intervention
D: Arm Label: WIC Program Participants; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Basilar Artery Occlusion: Endovascular Interventions vs Standard Medical Treatment
Brief Summary: This trial will provide valuable insights into the safety and efficacy of endovascular treatment for acute ischemic stroke patients with basilar artery occlusion within 8 hours of estimated occlusion time.


Options:
A: Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: standard medical therapy | Arm Label: endovascular + standard medical therapy; Type: EXPERIMENTAL; Interventions: Device: endovascular treatment, Other: standard medical therapy | Intervention Type: DEVICE; Name: endovascular treatment; Assigned to Arm(s): endovascular + standard medical therapy | Intervention Type: OTHER; Name: standard medical therapy; Assigned to Arm(s): endovascular + standard medical therapy, standard medical therapy
B: Arm Label: 1 Mechanical Embolectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Merci Retriever and Penumbra System | Arm Label: 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Merci Retriever and Penumbra System; Assigned to Arm(s): 1 Mechanical Embolectomy
C: Arm Label: RECO thrombectomy; Type: EXPERIMENTAL; Interventions: Device: RECO flow restoration device | Arm Label: Solitaire FR thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Solitaire FR flow restoration device | Intervention Type: DEVICE; Name: RECO flow restoration device; Assigned to Arm(s): RECO thrombectomy | Intervention Type: DEVICE; Name: Solitaire FR flow restoration device; Assigned to Arm(s): Solitaire FR thrombectomy
D: Arm Label: ADAPT Technique/Standard SR Group; Type: OTHER; Interventions: Other: Adapt/Standard Stent Retriever (SR) Group | Intervention Type: OTHER; Name: Adapt/Standard Stent Retriever (SR) Group; Assigned to Arm(s): ADAPT Technique/Standard SR Group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Acute Basilar Artery Occlusion: Endovascular Interventions vs Standard Medical Treatment
Brief Summary: This trial will provide valuable insights into the safety and efficacy of endovascular treatment for acute ischemic stroke patients with basilar artery occlusion within 8 hours of estimated occlusion time.


Options:
A: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA
B: Arm Label: standard medical therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: standard medical therapy | Arm Label: endovascular + standard medical therapy; Type: EXPERIMENTAL; Interventions: Device: endovascular treatment, Other: standard medical therapy | Intervention Type: DEVICE; Name: endovascular treatment; Assigned to Arm(s): endovascular + standard medical therapy | Intervention Type: OTHER; Name: standard medical therapy; Assigned to Arm(s): endovascular + standard medical therapy, standard medical therapy
C: Arm Label: Intravenous rtPA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous rtPA | Arm Label: Intravenous rtPA and Mechanical Thrombectomy; Type: EXPERIMENTAL; Interventions: Device: Mechanical thrombectomy, Drug: Intravenous rtPA | Intervention Type: DEVICE; Name: Mechanical thrombectomy; Assigned to Arm(s): Intravenous rtPA and Mechanical Thrombectomy | Intervention Type: DRUG; Name: Intravenous rtPA; Assigned to Arm(s): Intravenous rtPA, Intravenous rtPA and Mechanical Thrombectomy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV tpa (Alteplase) vs IA tpa (Alteplase) | Intervention Type: DRUG; Name: IV tpa (Alteplase) vs IA tpa (Alteplase); Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Mindfulness Based Childbirth and Parenting Education - RCT of Effects on Parent and Child Health
Brief Summary: The purpose of this study is to explore if an intervention using Mindfulness Based Childbirth and Parenting education (MBCP) targeted to stressed pregnant women is effective in: 1) reducing prenatal stress, 2) preventing perinatal maternal mental ill-health, 3) preparing the mother for labor and 4) promoting positive infant-caregiver attachment.


Options:
A: Arm Label: Mind in Labor (MIL); Type: EXPERIMENTAL; Interventions: Behavioral: Mind in Labor (MIL): Working with Pain in Childbirth | Arm Label: Treatment As Usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual (TAU) | Intervention Type: BEHAVIORAL; Name: Mind in Labor (MIL): Working with Pain in Childbirth; Assigned to Arm(s): Mind in Labor (MIL) | Intervention Type: BEHAVIORAL; Name: Treatment as usual (TAU); Assigned to Arm(s): Treatment As Usual (TAU)
B: Arm Label: antenatal classes in self hypnosis; Type: EXPERIMENTAL; Interventions: Behavioral: Self hypnosis | Arm Label: relaxation and awareness; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self hypnosis | Arm Label: Control; Type: OTHER; Interventions: Behavioral: Self hypnosis | Intervention Type: BEHAVIORAL; Name: Self hypnosis; Assigned to Arm(s): Control, antenatal classes in self hypnosis, relaxation and awareness
C: Arm Label: Therapy by iCBT; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Therapy by iCBT | Arm Label: Standard care-Counselling; Type: OTHER; Interventions: Other: Standard care-counselling | Intervention Type: BEHAVIORAL; Name: Therapy by iCBT; Assigned to Arm(s): Therapy by iCBT | Intervention Type: OTHER; Name: Standard care-counselling; Assigned to Arm(s): Standard care-Counselling
D: Arm Label: MBCP intervention; Type: EXPERIMENTAL; Interventions: Behavioral: MBCP | Arm Label: Control condition; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psychoprophylaxis | Intervention Type: BEHAVIORAL; Name: MBCP; Assigned to Arm(s): MBCP intervention | Intervention Type: BEHAVIORAL; Name: Psychoprophylaxis; Assigned to Arm(s): Control condition

Answer: D